First Trust NYSE Arca Biotechnology Index Fund
Latest First Trust NYSE Arca Biotechnology Index Fund News and Updates

Medivation Is for Sale: How Much Should It Get?
Considering the prospects for the pipeline, Medivation should get more than what Sanofi offered. It will probably get more than what Pharmacyclics received.

How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

What Analysts Think about Ionis
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

How Regeneron Is Working to Maintain Eylea’s Dominance
Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.

What Drove Regeneron’s 3Q16 Performance?
In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.

How Much Does Biogen Spend on Research and Development?
Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

Why Exelixis Stock Soared 46% in November
Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.

How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

Analysts Expect Incyte to Report Revenue Growth in Third Quarter
Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

A Financial Overview of Ionis Pharmaceuticals in October
Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.

Ionis Pharmaceuticals’ Revenue Stream
Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.

Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.

Estimates and Recommendations for Bluebird Bio on September 6
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.

How Analysts View BioMarin Pharmaceutical in August
On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.

What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.

Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.

Incyte’s Valuations on July 6
Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.

A Look at Ionis Pharmaceuticals’ January 2018 Valuation
On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.

Alnylam Is Preparing for Commercial Launch of Patisiran
To ensure the smooth commercial launch of investigational RNAi therapy Patisiran, Alnylam Pharmaceuticals (ALNY) has been actively involved in building its manufacturing, quality, and distribution infrastructure in the US and Europe.

Geographic Market Expansion to Boost Spinraza Sales in 2017
In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza reported sales worth $73 million from international markets.

How Gilead’s Other Products Performed in 2Q17
Apart from Gilead Sciences’ (GILD) antiviral drugs portfolio, the company also includes drugs from therapeutic areas like cardiovascular, inflammation, oncology, and respiratory products in its portfolio.

Nuplazid Expected to Become a Leading Central Nervous System Drug
On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.

Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

Ionis Reports Revenue Growth in 2Q17
Ionis (IONS) is a biopharmaceutical company that develops and commercializes RNA-targeted therapies.

The Rise of Amgen Stock in 2Q17
Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.

What Analysts Recommend for United Therapeutics in June 2017
Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”

Neurocrine Biosciences: Ingrezza, Collaborations, Ratings
In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia.

Ionis Pharmaceuticals’ Valuation Compared to Its Peers
According to March 20, 2017, data, Ionis stock has risen 4.1% over the last 12 months.

Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis
The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.

United Therapeutics: Will RemoSynch Become a Key Growth Driver?
United Therapeutics (UTHR) has developed a targeted strategy for a successful launch of its investigational drug device combination, the RemoSynch implantable pump system.

How Could Gilead Sciences Restore Its Growth?
With its continuous revenue fall, Gilead Sciences (GILD) could opt to restore its growth through acquisitions.

Why Neurocrine Biosciences May See Higher Losses in 2016
Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.

Why Europe Is an Important Market for Vertex’s Orkambi
Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.

Higher Discontinuations Are among Orkambi’s Concerns
Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.

How Ionis Pharmaceuticals’ Valuation Compares to Its Peers
Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.

ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016
If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.

Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know
Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.

Regeneron Pharmaceuticals’ Major Revenue Sources in 4Q15
Regeneron Pharmaceuticals (REGN) earns revenue from net product sales, collaboration, and technology licenses.

Orkambi: Recent Addition to the Vertex Portfolio
In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.

Pomalyst and Abraxane Revenues Are Critical for Celgene
Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.